Covid-19: Sanofi publishes positive results for its vaccine candidate

Sanofi released positive results for its vaccine candidate on Monday.

AFP - JOEL SAGET

Text by: RFI Follow

2 min

Sanofi back in the race for the anti-Covid-19 vaccine.

The French laboratory announces promising results for its phase 2 trial conducted with the British GSK.

Publicity

Read more

Late in

the vaccination race

, the French laboratory published positive results from a clinical trial on its main

Covid-19

vaccine project

on Monday

. The immune response in adults is strong at this stage of the trials, across all age groups. Phase 3 trials should therefore begin in the coming weeks at the international level and the laboratory says it has good hopes of having its candidate validated before the end of the year.

Finally good news for

the vaccine giant humiliated

by the start-ups BioNtech and Moderna which were the forerunners with their messenger RNA vaccine.

The first European pharmaceutical group, world champion of vaccines, preferred to rely on the traditional technique used for serum against influenza.

2nd messenger RNA vaccine project for 2022

Given the global shortage, the latter should easily find a taker.

Sanofi is also working on another anti-Covid-19 vaccine based on messenger RNA.

It will be available in 2022, at best.

Recently heard by the Senate, the CEO of the group bitterly defended himself, recalling that the industrialist is investing more than ever in research and development.

He spoke of the creation in the south-east of France of the most modern vaccine factory in the world.

Newsletter

Receive all international news directly in your mailbox

I subscribe

Follow all the international news by downloading the RFI application

google-play-badge_FR

  • Vaccines

  • France

  • Coronavirus

On the same subject

Covid-19: billionaire wants to help South Africa in vaccine production

reportage

Brazil: demonstrations in support of Bolsonaro, targeted by a parliamentary committee

Reportage

Covid: start of vaccination for 12-15 year olds in the United States